MondegarAI
Lion Point Capital, LP

Q3 2024 · 13F-HR

Lion Point Capital, LPholdings as filed

Filed 2024-11-14 · accession 0001013594-24-000964

$44.9M
Reported value
25
Positions
2024-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
464287655IWMISHARES TR$18.2M40.6%82,500PUTSOLE
457669307INSMINSMED INC$3.8M8.49%52,200CommonSOLE
374163103GERNGERON CORP$2.9M6.37%630,000CommonSOLE
039697107ARDXARDELYX INC$2.5M5.68%370,000CommonSOLE
59935V107MISTMILESTONE PHARMACEUTICALS IN$2.5M5.60%1,654,154CommonSOLE
G1110E107BHVNBIOHAVEN LTD$1.8M3.94%35,400CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$1.8M3.91%45,000PUTSOLE
G52694109KNSAKINIKSA PHARMACEUTICALS LTD$1.5M3.42%61,400CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$1.2M2.78%49,000CommonSOLE
56854Q200MRNS*MARINUS PHARMACEUTICALS INC$1.2M2.72%693,778CommonSOLE
31447P100FENCFENNEC PHARMACEUTICALS INC$1.1M2.39%215,000CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$956,6902.13%79,000CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$889,3501.98%46,200CommonSOLE
G29687103AVDLAVADEL PHARMACEUTICALS PLC$839,3601.87%64,000CommonSOLE
09609G100BLUEBIRD BIO INC$819,9041.83%1,578,256CommonSOLE
75901B107RGNXREGENXBIO INC$605,7981.35%57,750CommonSOLE
471871202JSPRJASPER THERAPEUTICS INC$601,9201.34%32,000CommonSOLE
254604101IRONDISC MEDICINE INC$378,3780.84%7,700CommonSOLE
08205P209BNTCBENITEC BIOPHARMA INC$358,4100.80%39,000CommonSOLE
03969K108ARQTARCUTIS BIOTHERAPEUTICS INC$326,4300.73%35,100CommonSOLE
81750R102MCRB1EURSERES THERAPEUTICS INC$322,3940.72%340,761CommonSOLE
55028X1094NX1LUMOS PHARMA INC$153,2090.34%39,589CommonSOLE
594918104MSFTMICROSOFT CORP$43,0300.10%100CommonSOLE
85209E109SPRUCE BIOSCIENCES INC$35,6180.08%75,000CommonSOLE
02079K107GOOGALPHABET INC$16,7190.04%100CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.